Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Jazz Pharmaceuticals (JAZZ) Misses Q4 EPS by 20c, Offers FY Guidance
February 23, 2021 4:13 PM ESTJazz Pharmaceuticals (NASDAQ: JAZZ) reported Q4 EPS of $4.00, $0.20 worse than the analyst estimate of $4.20. Revenue for the quarter came in at $665.5 million versus the consensus estimate of $639.55 million.
GUIDANCE:
Jazz Pharmaceuticals sees FY2021 EPS of $15.65-$16.86, versus the consensus of $16.78.... More
